New proline mimetics: Synthesis of thrombin inhibitors incorporating cyclopentane- and cyclopentenedicarboxylic acid templates in the P2 position. Binding conformation investigated by X-ray crystallography

Journal of Medicinal Chemistry

Volumn 43, Issue 9, 2000, Pages 1705-1713

  Nöteberg, Daniel ^a,e   Brånalt, Jonas ^a   Kvarnström, Ingemar ^a   Linschoten, Marcel ^b   Musil, Djordje ^b   Nyström, Jan Erik ^b   Zuccarello, Guido ^a   Samuelsson, Bertil ^b,c,d  

^a LINKÖPING UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c STOCKHOLM UNIVERSITY   (Sweden)

^d MEDIVIR AB   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DICARBOXYLIC ACID DERIVATIVE; INOGATRAN; MELAGATRAN; N [4 [AMINO(IMINO)METHYL]BENZYL] 2 (1 PIPERIDINYLCARBONYL) 2 CYCLOPENTENE 1 CARBOXAMIDE; N1 [4 [AMINO(IMINO)METHYL]BENZYL] N2 (2' CARBOXYLBENZYL) 1,2 CYCLOPENTANEDICARBOXAMIDE; N1 [4 [AMINO(IMINO)METHYL]BENZYL] N2 BENZYL 1,2 CYCLOPENTANEDICARBOXAMIDE; N1 [4 [AMINO(IMINO)METHYL]BENZYL] N2 BENZYL 2 CYCLOPENTENE 1,2 DICARBOXAMIDE; N1 [4 [AMINO(IMINO)METHYL]BENZYL] N2 CYCLOHEXYL 1,2 CYCLOPENTANEDICARBOXAMIDE; N1 [4 [AMINO(IMINO)METHYL]BENZYL] N2 CYCLOHEXYL 2 CYCLOPENTENE 1,2 DICARBOXAMIDE; N1 [4 [AMINO(IMINO)METHYL]BENZYL] N2 CYCLOHEXYL N2 ETHOXY 2 CYCLOPENTENE 1,2 DICARBOXAMIDE; N1 [4 [AMINO(IMINO)METHYL]BENZYL] N2 CYCLOHEXYL N2 ETHYL 1,2 CYCLOPENTANEDICARBOXAMIDE; N1 [4 [AMINO(IMINO)METHYL]BENZYL] N2 CYCLOHEXYL N2 ETHYL 2 CYCLOPENTENE 1,2 DICARBOXAMIDE; N1 [4 [AMINO(IMINO)METHYL]BENZYL] N2 CYCLOHEXYLMETHYL 2 CYCLOPENTENE 1,2 DICARBOXAMIDE; N1 [4 [AMINO(IMINO)METHYL]BENZYL] N2 PHENYL 2 CYCLOPENTENE 1,2 DICARBOXAMIDE; N1 [4 [AMINO(IMINO)METHYL]BENZYL] N2 PHENYL N2 ETHYL 2 CYCLOPENTENE 1,2 DICARBOXAMIDE; N1 [4 [AMINO(IMINO)METHYL]BENZYL] N2 [2' (METHYL)CARBOXYLBENZYL] 1,2 CYCLOPENTANEDICARBOXAMIDE; PROLINE DERIVATIVE; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

EID: 0041424038     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990557t     Document Type: Article

References (44)

1. (a) Navia, M. A.; Chaturvedi, P. R. Design Principles for Orally Bioavailable Drugs. Drug Discovery Today 1996, 1, 179.
2. (b) Kempf, D. J. Perspect. Drug Discovery Des. 1994, 2, 427.
3. (c) Adang, A. E. P.; Hermkens, P. H. H.; Linders, J. T. M.; Ottenheijm, H. C. J.; van Staveren, C. J. Case Histories of Peptidomimetics: Progression from Peptides to Drugs. Recl. Trav. Chim. Pays-Bas 1994, 113, 63.
4. Uzan, A. Antithrombotic Agents. Emerging Drugs 1998, 3, 189.
5. (a) Davie, E. W.; Fujikawa, K.; Kisiel, W. The Coagulation Cascade: Initiation, Maintanance, and Regulation. Biochemistry 1991, 30, 10363.
6. (b) Das, J.; Kimball, S. D. Thrombin Active Site Inhibitors. Bioorg. Med. Chem. 1995, 3, 999.
7. (c) Di Cera, E.; Vindigni, A.; Banerjee, D. Energetic Dissection of Specificity in Serine Proteases. Structure-Based Drug Design; Springer-Verlag: ISBN 3-540-63250-6, 1997; pp 19-84.
8. (a) Sanderson, P. E. J.; Naylor-Olsen, A. M. Thrombin Inhibitor Design. Curr. Med. Chem. 1998, 289.
9. (b) Brundish, D. E. Thrombin Inhibitors. Curr. Opin. Ther. Patents 1992, 1457.
10. (c) Exp. Opin. Ther. Patents 1997, 7, 651.
11. (d) Stone, S. R. Thrombin inhibitors. A New Generation of Antithrombotics. Trends Cardiovasc. Med. 1995, 5, 134.
12. (e) Ripka, W. C.; Vlasuk, G. P. Antithrombotics/Serine Proteases. In Annual Reports in Medicinal Chemistry; Bristol, J. A., Ed.; Academic: San Diego, 1997; Vol. 32, pp 71-89.
13. (f) Wiley, M. R.; Fisher, M. J. Small-molecule Direct Thrombin Inhibitors. Exp. Opin. Ther. Patents 1997, 7, 1265.
14. Bajusz, S. The Story of D-Phe-Pro-Arg-H, the Likely Anticoagulant of the Future. Biokémia 1990, 14, 127.
15. (a) Gustafsson, D.; Elg, M.; Lenfors, S.; Borjesson, I.; TegerNilsson, A. C. Effects of Inogatran, a new Low-Molecular Weight Thombin Inhibitor, in Rat Models of Venous and Arterial Thrombosis, Thrombolysis and Bleeding Time. Blood Coag. Fibrinolysis 1996, 7, 69.
16. (b) TegerNilsson, A. C.; Bylund, R.; Gustafsson, D.; Gyzander, E.; Eriksson, U. In vitro Effects of Inogatran, a Selective Low Molecular Weight Thrombin Inhibitor. Thromb. Res. 1997, 85, 133.
17. (a) Eriksson, H.; Eriksson, U.; Frison, L.; Thorsen, M. Intravenous treatment of Acute Deep Venous Thrombosis (DVT) with Melagatran, a Synthetic Low Molecular Weight Thrombin Inhibitor. Thromb. Haemostasis 1997, (Suppl.) OC-2411.
18. (b) Eriksson, B. I.; Carlsson, S.; Halvarsson, M.; Risberg, B.; Mattsson, C. Antithrombotic Effect of Two Low Molecular Weight Thrombin Inhibitors and a Low-Molecular Weight Heparin in a Caval Vein Thrombosis Model in the Rat. Thromb. Haemostasis 1997, 78, 1404.
19. (c) Gustafsson, D.; Antonsson, T.; Bylund, R.; Eriksson, U.; Gyzander, E.; Nilsson, I.; Elg, M.; Mattsson, C.; Deinyúm, J.; Pehrsson, S.; Karlsson, A.; Sörensen, H. Effects of Melagatran, a New Low-molecular-weight Thrombin Inhibitor, on Thrombin and Fibrinolytic Enzymes. Thromb. Haemostasis 1998, 79, 110.
20. 1-ketoarginineamide Derivatives: a Novel Class of Serine Protease Inhibitors. Bioorg. Med. Chem. Lett. 1997, 7, 315.
21. (b) Harmat, N. J. S.; Di Bugno, C.; Criscuoli, M.; Giorgi, R.; Lippi, A.; Martinelli, A.; Monti, S.; Subissi, A. 1,2-Disubstituted Cyclohexane Derived Tripeptide Aldehydes as Novel Selective Thrombin Inhibitors. Bioorg. Med. Chem. Lett. 1998, 8, 1249.
22. Turbanti, L.; Cerbai, G.; Di Bugno, C.; Giorgi, R.; Garzelli, G.; Criscuoli, M.; Renzetti, A. R.; Subissi, A.; Bramati, G.; DePriest, S. A. 1,2-Cyclomethylenecarboxylic Monoamide Hyddroxamic Derivatives. A Novel Class of Non-Amino Acid Angiotensin Converting Enzyme Inhibitors. J. Med. Chem. 1993, 36, 699.
23. Hart, S. A.; Sabat, M.; Etzkorn, F. A. Enantio- and Regioselective Synthesis of a (Z)-Alkene cis-Proline Mimic. J. Org. Chem. 1998, 63, 7580-7581.
24. Goldsworthy, L. J.; Perkin, W. H. Resolution of trans-Cydopentane-1:2-Dicarboxylic Acid. J. Chem. Soc. 1914, 2639.
25. Morimoto, Y.; Terao, Y.; Achiwa, K. Enzymes and Catalysts. I. Pig Liver Esterase-Catalyzed Hydrolysis of Heterocyclic Diesters. Chem. Pharm. Bull. 1987, 35, 2266.
26. (a) Studer, A.; Hintermann, T.; Seebach, D. Synthesis and First Applications of a New Chiral Auxiliary (tert-Butyl 2-(tert-Butyl)-5,5-dimethyl-4-oxoimidazolidine-1-carboxylate). Helv. Chim. Acta 1995, 78, 1185.
27. (b) Roush, W. R.; Gillis, H. R.; Ko, A. I. Stereochemical Aspects of the Intramolecular Diels-Alder Reactions of Deca-2,7,9-trienoate Esters. 3. Thermal Lewis Acid Catalyzed, and Asymmetric Cyclizations. J. Am. Chem. Soc. 1982, 104, 2269.
28. (c) Horton, D.; Usui, T. Synthesis of Optically Pure di-to tetra-Substituted Cyclopentanes from Sugar-Derived Norbornene Derivatives. Carbohydr. Res. 1991, 51.
29. (d) Langer, T.; Illich, M.; Helmchen, G. Diastereoselective Oxidative Coupling of Chiral Carboxylic Acid Derivatives. Tetrahedron Lett. 1995, 36, 4409.
30. (d) Misumi, A.; Iwanaga, K.; Furuta, K. Yamamoto, H. Simple Asymmetric Construction of Carbocyclic Framework. Direct Coupling of Dimenthyl Succinate with 1,ω-Dihalides. J. Am. Chem. Soc. 1985, 107, 3343.
31. (e) Furuta, K.; Iwanaga, K.; Yamamoto, H. Condensation of (-)-Dimenthyl Succinate Dianion with 1,ω-Dihalides: (-)-(1S,2S)-Cyclopropane-1,2-Dicarboxylic Acid. Org. Synth. 1988, 67, 76.
32. (a) Nöteberg, D.; Brånalt, J.; Kvarnström, I.; Classon, B.; Samuelsson, B.; Nillroth, U.; Danielson, U. H.; Karlén, A.; Hallberg, A. Synthesis of Enantiomerically Pure cis and trans 2-Aminocyclopentanecarboxylic Acids. Use of Proline Replacements in Potential HIV-Protease Inhibitors. Tetrahedron 1997, 53, 7975.
33. (b) Rosenquist, Å.; Kvarnström, I.; Svensson, S. C. T.; Classon, B.; Samuelsson, B. Synthesis of Enantiomerically Pure trans-3,4-Substituted Cyclopentanols by enzymatic resolution. Acta Chem. Scand. 1992, 46, 1127.
34. 13b
35. 13c
36. Lila, C.; Gloanc, P.; Cadet, L.; Hervé, Y.; Fournier. J.; Leborgne, F.; Verbeuren, T. J.; De Nanteuil, G. Large Scale Preparation of Protected 4-Aminomethylbenzamidine. Application to the Synthesis of the Thrombin Inhibitor, Melagatran. Synth. Commun. 1998, 28, 4419.
37. For compound 6 the reaction sequence was altered: the coupling product was treated with NaOH in aqueous dioxane to hydrolyze the ester prior to the hydrogenation step.
38. 2. Chem Pharm. Bull. 1988, 36, 15.
39. Stevens, H. C.; Rinehart, J. K.; Lavanish, J. M.; Trenta, G. M. The Hydrolysis of 7,7-Dichlorobicyclo[3.2.0]hept-2-en-6-one. J. Org. Chem. 1971, 36, 2780.
40. 19 shows that the absolute configuration of this bisester is S. Chiral HPLC showed that (-)-11 and (+)-11 had an ee > 90%.
41. Skrzypczak-Jankun, E.; Carperos, V. E.; Ravichandran, K. G.; Tulinsky, A. Structure of the Hirugen and Hirulog 1 Complexes of α-Thrombin. J. Mol. Biol. 1991, 221, 1379.
42. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. Methods Enzymol. 1997, 276, 307.
43. Collaborative Computational Project, Number 4. The CCP4 Suite: Programs for Protein Crystallography. Acta Crystallogr. 1994, D50, 760.
44. Brünger, A. T. X-PLOR, α System for X-ray Crystallography and NMR; Yale University Press: New Haven, CT, 1992.